Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (USFDA). The company’s Tadalafil Tablets 20mg is AB-rated generic therapeutic equivalent version of Eli Lilly & Company’s Adcirca.
It is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. According to IQVIA (IMS Health), Adcirca and its generic equivalents had US sales of approximately $490 million for the 12-month period ending November 2018. The product is available for shipping immediately.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1528.20 |
Dr. Reddys Lab | 5872.35 |
Cipla | 1405.95 |
Zydus Lifesciences | 997.45 |
Lupin | 1638.40 |
View more.. |